Solute carrier family 22 member 12

Description:

Description
  • Accession: Q96S37
  • Swissprot: S22AC_HUMAN
  • Organism: Homo sapiens
  • Gene: SLC22A12
  • Target class: Transporter

Drug Relations:

benzbromarone
Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout. Bioactivity details MOA
lesinurad
Lesinurad reduces serum uric acid levels by inhibiting the function of transporter proteins involved in uric acid reabsorption in the kidney. Lesinurad inhibited the function of two apical transporters responsible for uric acid reabsorption, uric acid transporter 1 (URAT1) and organic anion transporter 4 (OAT4), with IC50 values of 7.3 and 3.7 μM, respectively. URAT1 is responsible for the majority of the reabsorption of filtered uric acid from the renal tubular lumen. OAT4 is a uric acid transporter associated with diuretic-induced hyperuricemia. Bioactivity details MOA
sulfinpyrazone
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. Bioactivity details MOA
benzarone
antihemorrhagic agent; structure Bioactivity details MOA
probenecid
The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. Bioactivity details MOA